Dr. David Horn Solomon, PhD
Chairman of the Board
David Horn Solomon has extensive experience in the biotech sector as a CEO and board member, as well as an investor. He was previously the CEO of Silence Therapeutics (LON: SLN), a UK-listed biotech company developing RNAi-based therapeutics to treat conditions with a high unmet medical need.
Previously, David served as CEO of Akari Therapeutics (NASDAQ: AKTX), Managing Partner at Sund Capital, a specialized Nordic-focused healthcare investment fund, and CEO of Bionor Pharma ASA. From 2008 to 2015, he was CEO of Zealand Pharma A/S (NASDAQ: ZEAL), during which time Adlixin®, the company’s lead product for the treatment of type II diabetes, was approved in the US. Adlixin® is now marketed by Sanofi as a monotherapy and in combination with Lantus as Soliqua®.
From 2003 to 2006, David headed healthcare investments at Carrot Capital Healthcare Ventures in New York City. He is a former member of the board of directors of TxCell SA (acquired by Sangamo in 2018), Onxeo SA (Euronext Paris: ONXEO) and was Chairman of Promosome LLC (La Jolla, CA).
David studied at Weill Cornell Medicine of Cornell University where he earned his Ph.D and served on the faculty of the College of Physicians and Surgeons at Columbia University, both located in New York City.
Catherine Dunand has held several executive posts in the pharmaceutical industry, among them, International Marketing Manager, Head of International Marketing and Head of International Profit Centers. Working with companies such as Roussel Uclaf and Hoechst Marion Roussel (now parts of Sanofi), Catherine has also conducted several mergers and acquisitions assignments, and reorganization projects.
Following her work in the pharmaceutical industry, she served as the Chief Executive Officer of several small- and mid-cap corporations, leading two successive leveraged buyouts.
For the last eight years, Catherine has dedicated herself to consulting and non-executive assignments for growing SMEs, including family-owned companies, listed companies and private equity funds. She also holds minority stakes in several private equity investments.
Following the sale of the pharmaceutical company HRA, Catherine helped to found Cemag Invest, a family office investing in healthcare and business-to-business services. She currently serves as the company’s CEO.
Catherine holds degrees from Ecole Centrale de Lyon and INSEAD (MBA), and received her non-executive director certification from Sciences Po/IFA (Institut Français des Administrateurs).
Charlotte Sibley’s career in the healthcare industry spans forty years, and includes contributing her expertise in market research at Pfizer, and in the medical device sector at Johnson & Johnson. Over the course of her career, Charlotte has also expanded her expertise to the areas of global pharma at Bristol-Myers Squibb and Pharmacia (now Pfizer), biotech at Millennium Pharmaceuticals (now Takeda Oncology), and consumer products at Lipton. She established the US operations for a leading UK-based market research company, achieving profitability in eighteen months in a highly competitive environment. Charlotte also worked as a security analyst for the pharmaceutical industry at Donaldson, Lufkin & Jenrette in New York.
Charlotte was named 2008 Woman of the Year by the Healthcare Businesswomen’s Association in recognition of her leadership, business expertise and mentoring. She was also among those named in PharmaVoice’s Most Inspiring People in Pharma in 2006. She serves on the Boards of Directors of privately held Taconic Biosciences, Inc. and Fort Hill Company. Through 2014 she was a member of the Board of American Pacific Corporation (NASDAQ: AMPAC), a leading custom manufacturer of pharmaceutical ingredients and propulsion products.
Charlotte holds an MBA in Finance and Marketing from the University of Chicago Booth Graduate School of Business, and is a National Association of Corporate Directors (NACD) Board Leadership Fellow and Governance Fellow.
Françoise Brunner-Ferber, PhD
Françoise Brunner-Ferber has more than twenty-five years of clinical pharmacology experience, working for Merck Sharp and Dohme, Johnson and Johnson, and later for Marion Merrell Dow through its mergers with Hoechst Marion Roussel and Aventis. She spent seven years as Head of the Zurich Subregion (MSD) and subsequently ten years as Senior Director and Head of Clinical Pharmacology Europe. Her responsibilities included strong interfaces with preclinical development and research groups, aiming at a coordinated drug development strategy across the Atlantic. She has a keen interest in animal models, first-in-man studies, surrogate markers, and PK/PD relationship to support mechanisms of action and dose selection. She founded Brunner Naga, a consulting company, in 2001.
Françoise holds a Doctorate in Clinical Pharmacology and a Bachelor’s in Medicinal Chemistry from the University of Geneva (Switzerland).
Jean-Michel Petit heads the venture capital practice of IRDI Gestion, where he manages the seed fund IRDInov, investing in start-ups located in the southwest of France. He serves on the boards of several portfolio companies such as Gamamabs, Fineheart, EnobraQ, Telecom Design, Ademtech and LDL Technology. Before joining IRDI Gestion, Jean-Michel spent four years at CDP Capital as part of the Life Sciences venture capital team, based initially in Montréal and then in Paris, where he made a range of international investments (mostly in the US). Prior to CDP Capital, he worked for a regional fund based in Montréal, Canada.
Jean-Michel graduated from Chimie ParisTech and holds an M.Sc. from Montréal University, as well as an MBA from McGill University (Montréal, Canada).
Luc-André Granier, MD, PhD
Chief Executive Officer, Medical Director & Co-Founder
Luc-André Granier co-founded Advicenne in 2007 and is the company’s CEO and Medical Director. He is an expert in the pharmaceutical development of innovative therapeutic products in the field of the central nervous system, and brings to Advicenne more than twenty-five years of experience in the pharmaceutical and biotech industries.
In his work with companies such as Eli Lilly and Company, Synt:em and Forenap, Luc-André has overseen a number of clinical trials and led numerous programs for the development of drugs to treat neurological disorders, primarily in the areas of pain, migraine, neuro-degenerative diseases and psychiatric disorders. He was responsible for the successful proof of concept study for the “blockbuster” duloxetine (Cymbalta, Xeristar, Yentreve), approved by the FDA in 2004.
Luc-André holds Doctor of Medicine and Doctor of Science degrees from Louis Pasteur University (Strasbourg, France), where he specialized in biochemistry, and molecular and cellular biology. He is a member of several national and international scientific societies in the fields of pain, epilepsy and renal diseases, including the International League Against Epilepsy (ILAE), American Society of Nephrology (ASN) and the International Pediatric Nephrology Association (IPNA).
Philippe Boucheron has more than twenty years of life science investment experience and currently serves as Deputy Chief of Life Sciences Investment at Bpifrance.
From 1993 to 1996, Philippe worked as an associate at BioCapital LP, one of the largest Canadian venture capital funds focusing on healthcare. In 1997, he joined the mid-cap equity research team at ING Barings Ferri, Paris, which he directed until 2000 and where he spent a significant part of his time following French and European listed biotech companies.
In 2000, he co-founded Bioam Funds, dedicated to early-stage life science investments, serving as Investment Manager, then, in 2004, as Managing Partner. After the merger of Bioam with CDC Entreprises in July 2010, Philippe joined the CDC Entreprises life sciences team as Investment Manager.
CDC Entreprises, FSI and Oséo merged to create Bpifrance in 2013. Since then, Philippe has served as Deputy Chief of the Life Sciences Investment Business Unit and sits on the company’s Investment Committee. He also serves on the boards of Ademtech, Integragen, SSI, ART, Supersonic Imagine and CorWave.
Philippe holds degrees in Biochemical Engineering and Microbial Genetics from the National Institute of Applied Sciences in Toulouse (INSA), an MSc in Biochemical Engineering from Ecole Polytechnique (Montréal, Canada) and an MBA from INSEAD.
Thibaut Roulon, PhD
Thibaut Roulon is currently Investment Director of Life Science Investments at Bpifrance. A scientist by training, he has been an investor since 2005, when he joined Bioam Gestion, a venture capital firm investing in life sciences companies. In 2010, Bioam merged with CDC Entreprises, a leading French private equity firm. Thibaut is responsible for managing investments in life sciences companies through Bioam and InnoBio funds.
Thibaut started his career as a scientist at Anosys Inc. (Menlo Park, CA, USA), a company developing cancer immunotherapeutics. He is a graduate of the Ecole Centrale de Paris and holds a PhD from Pierre and Marie Curie University.
André Ulmann, MD, PhD
Non-voting member (Censor)
André Ulmann’s career spans some thirty years in research and the pharmaceutical industry, as well as in medical practice. He serves as an active advisor to Advicenne from conception through drug development.
André is currently a Director of HRA Pharma, which he founded and managed until 2009 before assuming the presidency. In 1999, HRA Pharma launched Norlevo, better known as the “morning-after pill.” Norlevo is now available in more than fifty countries and has made HRA Pharma a pioneer in emergency contraception. Under André’s leadership, HRA Pharma has become a socially-conscious pharmaceutical company that designs and develops medical products and devices for the treatment of rare diseases and unmet medical needs.
André is a Doctor of Medicine and Doctor of Science, and began his career practicing Nephrology at Hôpital Necker (Paris, France).
Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.
© 2019 Advicenne